Fritextsökning
Artiklar per år
Innehållstyper
-
She creates pharmaceuticals on a 3D printer
The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a well-advanced project with 3D-printed drugs at Uppsala University. “It will soon be available in clinics”, says Christel Bergström, who is heading the project.
-
Swedish breakthrough in Alzheimer’s: “We can finally present great data”
Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.
-
“We need to build flexible operating theatres”
Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas that three specialist surgeons are suggesting for the operating theatre of the future.
-
Business Sweden’s new team is rolling out the blue-yellow carpet
According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta Stenson.
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s
-
Gel av spindeltrådsprotein utvecklas för biomedicinsk användning
Spindeltrådens märkliga egenskaper kommer till användning när svenska forskare undersöker nya, potentiella metoder för bland annat regenerativ medicin och läkemedelsformulering.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
Elicera develops CAR-T against solid tumours – may become the first in the world
Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.
-
Life Science Sweden´s international issue is on its way
A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.
-
The route to vaccines for everyone: “We did not just sit around and wait”
The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.
-
Theranos-skandalen – så gick det till när Elizabeth Holmes lurade USA:s toppinvesterare
Biotechbolaget Theranos var ett av de mest hyllade amerikanska företagen och dess vd Elizabeth Holmes blev en av USA:s yngsta miljardärer. Men 2015 vände allt för den framgångsrika entreprenören och sedan gick det bara utför. I början av den här månaden dömdes hon för bedrägeri av en domstol i Kalifornien.
BREAKING